AGENDA
Utah Department of Health
Pharmacy and Therapeutics Committee
Thursday, July 16, 2015
7:00 a.m. to 8:30 a.m.
Cannon Health Building
Room 128
Please note that persons who wish to address the P&T Committee may contact Utah Medicaid at (medicaidpharmacy@utah.gov) at least 7 calendar days prior to the meeting. Comments from visitors, while welcome, may be limited due to time constraints
1) Welcome and Introductions - Kort Delost, R.Ph., Chair
a) Review and Approval of Minutes
b) Update on PDL Administration - Robyn Seely, Pharm.D., Trevor Smith, C.Ph.T.
c) Housekeeping
i) Welcome to Utah Medicaid Pharmacy Director Chad Hope
ii) Chairperson Election
2) July Review: Hepatitis C Combination Agents
Agents to include: Ledipasvir/Sofosbuvir (Harvoni) and Ombitasvir/Paritaprevir/Ritonavir/Dasabuvir (Viekira Pak)
i) Other States Report - Trevor Smith, C.Ph.T
ii) Public Comment
(1) Laura L. Hill, PharmD, Medical Outcomes Science Liaison, Abbive for Viekira Pak
(2) Michele Puyear, Associate Director, Gilead
iii) Board Discussion/Questions
iv) Board Action
3) July Review: Agents used to treat Angina
Agents to include: Nitroglycerin, Ranolazine, Amyl Nitrite, Isosorbide Dinitrate, Isosorbide Mononitrate
i) Other States Report - Trevor Smith, C.Ph.T
ii) Public Comment
iii) Board Discussion/Questions
iv) Board Action
4) Next Meeting August 20, 2015 (Antiretroviral, Protease Inhibitors)
5) Adjourned - .Kort Delost, R. Ph., Chair
Public comment that responds to the materials presented by the College of Pharmacy @University of Utah is most helpful. The foundation documents used for most reviews are prepared by the Oregon Evidence-based Practice Center or the University of Utah, College of Pharmacy, and are posted in advance on the P&T Committee website. Manufacturers are requested to submit any additional materials they would like reviewed as part of the process to:
Dr. Gary Oderda
College of Pharmacy
30 South 2000 East
SLC, UT 84112-5820
All materials must be clearly labeled that they are submitted for consideration as part of the state of Utah Medicaid Preferred Drug List Program review process. Materials must be received at least 60 days before the scheduled review date. Materials most useful to support the evidence-based process include any new evidence (information from clinical trials or studies when possible) after the Oregon monograph was prepared, unpublished materials the company would like considered as part of the process, or any other materials not likely to be included in a literature search.
Tentative 2015 Pharmacy & Therapeutics Committee Schedule
Month Topic Agents
8/20/2015 Antiretroviral, Protease Inhibitors Atazanavir, Atazanavir/Cobicistat, Darunavir, Fosamprenavir, Indinavir, Lopinavir/Ritonavir, Nelfinavir, Ritonavir, Saquinavir, Tipranavir
9/17/2015 Agents used to Treat Irritable Bowel Syndrome (IBS) Alosetron, Linaclotide, Lubiprostone
Bowel Cleansing/Prep Agents Polyethylene Glycol 3350, Polyethylene Glycol-Electrolyte Solution, Sodium Picosulfate/Magnesium Oxide/Citric Acid, Sodium Sulfate/Potassium Sulfate/Magnesium Sulfate, Sodium Sulfate/Potassium Sulfate/Magnesium Sulfate/Polyethylene Glycol-Electrolyte Solution
10/15/2015 Immune Globulin Agents Bivigam, Carimune NF, Flebogamma, Flebogamma DIF, GamaSTAN S/D, Gammagard, Gammagard S/D, Gammagard S/D Less IgA, Gammaked, Gammaplex, Gamunex-C, Hizentra, Hizentra 20%, Octagam, Privigen
11/19/2015 Ophthalmic Beta-Adrenergic Antagonists Betaxolol, Carteolol, Levobunolol, Metipranolol, Timolol and all combination agents
Ophthalmic Cholinergic Agonists Acetylcholine, Carbachol, Pilocarpine
12/17/2015 Ophthalmic Muscarinic Antagonists Atropine, Scopolamine, Homatropine, Cyclopentolate, Tropicamide
Ophthalmic Miscellaneous Agents TBD
1/21/2016 Beta-Lactams/Clavulanate Combos Amoxicillin, Amoxicillin/Clavulanate, Ampicillin, Ampicillin/Sulbactam, Cloxacillin, Dicloxacillin, Nafcillin, Oxacillin, Penicillin, Piperacillin, Piperacillin/Tazobactam, Ticarcillin/Clavulanate
Notice of Special Accommodations (ADA)
NOTICE OF SPECIAL ACCOMMODATION DURING PUBLIC MEETINGS
In compliance with the Americans with Disabilities Act, individuals needing special accommodations (including auxiliary communicative aids and services) during this meeting should notify Trevor Smith at 801-538-7008.